Dr. Banta-Green studies substance use involving opioids and stimulants and interventions to support recovery and reduce substance-related harms. He is particularly interested in developing interventions that are accessible to all people, including those who are most marginalized, such as those who are unhoused, utilizing services syringe service programs, and/or in the criminal legal system. He provides technical assistance and evaluation services for public health and safety interventions including the website http://stopoverdose.org, and information for the general public and professionals about effective treatments at http://learnabouttreatment.org. As an epidemiologist he develops innovative approaches to measuring the use and impacts of substances as well as service utilization. His health services research involves clinical trials, implementation research, and secondary data analyses. He serves on local, state, and federal workgroups and committees related to epidemiology, policy, and interventions for illicit substance-related problems. He is a member of the U.S. Health and Human Service’s Interdepartmental Substance Use Disorders Coordinating Committee.
Anthony is a Research Associate Professor, providing clinical trial and regulatory expertise in the treatment and prevention of substance use disorder, in particular opioid use disorder. He has directed numerous clinical trials and program evaluations in both community treatment and emergency department settings. Dr. Floyd has a secondary focus in firearm injury prevention research, which examines many of the same underlying public health concerns as substance use disorder. In addition, Anthony leads a team from Washington in a multi-site, multi-state study, examining the effectiveness of an opioid safety and education training program aimed at pharmacists in community-based settings.
Anna Sunshine completed her medical school, graduate school and psychiatry training at the University of Washington. Her graduate training was completed in the Department of Genome Sciences where she used high-throughput sequencing approaches to study the biological effects of complex genetic changes in the model organism Saccharomyces cerevisiae.
Connecting her background in genomics with psychiatry, Dr. Sunshine’s research now focuses on identifying genetic risk factors for schizophrenia and characterizing the biological effects of these risk alleles using induced pluripotent stem cell (iPSC) systems. Dr. Sunshine engages individuals living with schizophrenia and their families in research to further our current understanding of schizophrenia biology and help lay groundwork for future treatment development.
My primary areas of research include artificial intelligence, AI/machine ethics, behavioral health technologies, telemedicine, telehealth, forensic psychology, and military and Veteran population health. I’ve consulted widely on the topic of military and veteran health and technology in healthcare and have helped to develop national guidelines for telemental health, clinical best practices for technology-based treatments, and standards for human-AI interaction transparency. My vision is to build, and help others to build, technologies that help promote behavioral change and that improve the lives of people.
Jill Locke, Ph.D., is an Associate Professor in the UW Department of Psychiatry and Behavioral Sciences, a licensed child psychologist and the former co-Director of the SMART Center from 2020-23. To date, her research has focused on the: 1) presentation of social impairment for autistic youth; 2) identification of best practices for autistic youth; and 3) understanding of successful implementation and sustainment of evidence-based practices (EBPs) for autistic youth in public school settings. Her current research focuses on understanding EBP use to support autistic youth in inclusive settings and developing and testing implementation strategies to support the adoption, implementation, and sustainment of EBPs in public schools.
Dr. Neuhaus has a broad research focus on social-emotional processes in individuals with neurodevelopmental disorders, particularly children with autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), or inherited or de novo genetic events. Dr. Neuhaus’s research is informed by a number of methodological approaches, including clinical/behavioral assessment and physiological measures such as EEG and autonomic biomarkers. Dr. Neuhaus is particularly interested in how social and emotional processes relate to brain function and development, and in how they interact with one another to influence diagnostic outcomes (e.g., phenotypes within autism) and psychiatric trajectories over the course of development. Clinically, Dr. Neuhaus specializes in diagnostic assessment of ASD.
I am a perinatal and addiction psychiatrist and Acting Assistant Professor in the Department of Psychiatry and Behavioral Sciences. My main area of interest and expertise is substance use disorders in the perinatal period as well as women’s mental health more generally. I am also passionate about doing my part to address inequities in healthcare.
I completed my adult psychiatry residency at the University of California, Davis and went on to complete my child & adolescent psychiatry fellowship at Seattle Children’s. My clinical work is focused on inpatient psychiatry and psychopharmacology. I have a particular interest in working with families and children in management of disruptive behavior disorders.
